
On Wednesday, May 18, Clearmind Medicine Inc. (OTC:CMNDF) will meet with the Center for Drug Evaluation and Research (CDER), a department within the FDA.
The objective of the meeting is to discuss Clearmind’s proposed first-in-human study evaluating its proprietary drug candidate CMND-100, developed for the treatment of alcohol use disorder. Clearmind could later submit an investigational new drug application.